Last reviewed · How we verify
BMS-986205 tablet with free base — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BMS-986205 tablet with free base (BMS-986205 tablet with free base) — Bristol-Myers Squibb.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BMS-986205 tablet with free base TARGET | BMS-986205 tablet with free base | Bristol-Myers Squibb | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BMS-986205 tablet with free base CI watch — RSS
- BMS-986205 tablet with free base CI watch — Atom
- BMS-986205 tablet with free base CI watch — JSON
- BMS-986205 tablet with free base alone — RSS
Cite this brief
Drug Landscape (2026). BMS-986205 tablet with free base — Competitive Intelligence Brief. https://druglandscape.com/ci/bms-986205-tablet-with-free-base. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab